Covered recipient · General Payments record
STUART A GREEN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2024
$9,673.43
- Reported across 265 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $357.49 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $142.22 | 6 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65.11 | 2 |
| Amgen Inc. | $62.58 | 3 |
| Janssen Biotech, Inc. | $28.57 | 1 |
| Kiniksa Pharmaceuticals International, plc | $21.62 | 1 |
| ABBVIE INC. | $19.49 | 1 |
| Aurinia Pharma U.S., Inc. | $17.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.49 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103833732 | CMS |
| Amgen Inc. | $13.27 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115678515 | CMS |
| Amgen Inc. | $25.32 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117567086 | CMS |
| Amgen Inc. | $23.99 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117567088 | CMS |
| Aurinia Pharma U.S., Inc. | $17.90 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150681133 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.95 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117847969 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.16 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117847971 | CMS |
| Janssen Biotech, Inc. | $28.57 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078411398 | CMS |
| Kiniksa Pharmaceuticals International, plc | $21.62 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154856719 | CMS |
| PFIZER INC. | $27.08 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132041073 | CMS |
| PFIZER INC. | $20.42 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132053400 | CMS |
| PFIZER INC. | $29.40 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132049508 | CMS |
| PFIZER INC. | $23.59 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132067133 | CMS |
| PFIZER INC. | $24.13 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132063592 | CMS |
| PFIZER INC. | $17.60 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131125625 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.